We are live on
!
Find out more
PBA
Paradigm Biocapital Advisors Portfolio holdings
AUM
$4.89B
1-Year Est. Return
251.12%
This Fund
S&P 500
This Quarter
Est. Return
+1.76%
1 Year Est. Return
+251.12%
3 Year Est. Return
+670.11%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.47B
AUM Growth
+$179M
(+14%)
Cap. Flow
+$251M
Cap. Flow
% of AUM
17.06%
Top 10 Holdings %
Top 10 Hldgs %
60.67%
Holding
38
New
8
Increased
19
Reduced
3
Closed
7
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Disc Medicine
IRON
|
+$63.6M |
| 2 |
argenx
ARGX
|
+$58.3M |
| 3 |
TG Therapeutics
TGTX
|
+$50.5M |
| 4 |
Olema Pharmaceuticals
OLMA
|
+$41.5M |
| 5 |
BCYC
Bicycle Therapeutics
BCYC
|
+$37.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
|
+$61.5M |
| 2 |
ONC
BeOne Medicines Ltd
ONC
|
+$38.5M |
| 3 |
Incyte
INCY
|
+$29.6M |
| 4 |
Vir Biotechnology
VIR
|
+$24.9M |
| 5 |
Madrigal Pharmaceuticals
MDGL
|
+$19.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.49% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Roivant Sciences
ROIV
$25B
| $12.6M | 0.86% |
+1,081,767
| New | +$12.2M |
|
27
Kura Oncology
KURA
$841M
| $11.1M | 0.75% |
1,212,828
+207,920
| +21% | +$2.11M |
|
|
CMPS
28
Compass Pathways
CMPS
$1.59B
| $10.1M | 0.68% |
+1,358,709
| New | +$12M |
|
|
ETNB
29
CALL
DELISTED
89bio
ETNB
| $5.08M | 0.34% |
+329,100
| New | +$5.52M |
|
|
AMAM
30
CALL
DELISTED
Ambrx Biopharma Inc
AMAM
| $2.41M | 0.16% |
+209,600
| New | +$2.85M |
|
31
Cogent Biosciences
COGT
$7.32B
| $2.2M | 0.15% |
+225,605
| New | +$2.68M |
|
|
32
PUT
argenx
ARGX
$52.8B
| – | – |
-150,000
| Closed | -$58.5M |
|
|
33
Madrigal Pharmaceuticals
MDGL
$11.7B
| – | – |
-85,000
| Closed | -$19.6M |
|
34
MoonLake Immunotherapeutics
MLTX
$1.53B
| – | – |
-369,615
| Closed | -$18.9M |
|
|
35
Vir Biotechnology
VIR
$1.55B
| – | – |
-1,014,239
| Closed | -$24.9M |
|
|
ONC
36
BeOne Medicines Ltd
ONC
$33.5B
| – | – |
-216,093
| Closed | -$38.5M |
|
|
KRTX
37
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| – | – |
-283,605
| Closed | -$61.5M |
|
|
THRX
38
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
| – | – |
-1,950,327
| Closed | -$18.2M |
|
Similar funds
KCM
DGI
FC
MCM
MCCA
SIA
SCA
SMFG
Paradigm Biocapital Advisors's Q3 2023 Portfolio in Review
As of Q3 2023, Paradigm Biocapital Advisors held 38 positions worth $1.47B, up 14% from $1.29B the previous quarter. Its ten largest holdings account for 61% of the portfolio.
Paradigm Biocapital Advisors deployed $251M of net new capital in Q3 2023, opening 8 new positions and adding to 19 existing holdings. Its largest new stake was Disc Medicine: 1,272,279 shares worth $59.8M.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 95% a quarter earlier.
On the sell side, the largest reduction was Incyte, an estimated $29.6M trimmed.
- Paradigm Biocapital Advisors's largest Q3 2023 buy was Disc Medicine: 1,272,279 shares worth $59.8M.
- Paradigm Biocapital Advisors added most to argenx in Q3 2023, an estimated $58.3M increase.
- Paradigm Biocapital Advisors's biggest Q3 2023 reduction was Incyte, cutting an estimated $29.6M.
- Paradigm Biocapital Advisors fully exited Karuna Therapeutics, Inc. Common Stock in Q3 2023, selling an estimated $61.5M.
- Paradigm Biocapital Advisors's ten largest holdings make up 61% of its $1.47B portfolio in Q3 2023.
- Paradigm Biocapital Advisors opened 8 new positions and closed 7 in Q3 2023.
- Paradigm Biocapital Advisors's portfolio value rose 14% quarter-over-quarter to $1.47B.
Based on Paradigm Biocapital Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.